Moreover, due to its histology-agnostic approval for solid tumors with BRAF V600E mutations, this regimen is now also indicated for papillary and poorly differentiated thyroid cancers. The gene discussed is BRAF; the disease is poorly differentiated thyroid gland carcinoma.